Andrew Melber

Andrew Melber is a Senior Scientist at Intellia Therapeutics, Inc. since September 2023, with prior experience as a Scientist II at Takeda, where leadership in preclinical biology discovery for gene therapy programs targeting lysosomal storage diseases was demonstrated. Andrew's expertise includes assay development and execution within pharmaceutical settings, focusing on metabolic diseases and gene therapy. In previous roles, Andrew contributed to compound selection and efficacy studies at Eurofins PSS Insourcing Solutions and Comet Therapeutics, along with significant postdoctoral research at the University of Massachusetts Medical School, encompassing CRISPR applications and mitochondrial function analysis. Academic credentials include a Ph.D. in Biochemistry from the University of Utah and a Bachelor's Degree in Molecular Biology from Juniata College.